S&C’s Senior M&A Partner Frank Aquila spoke to the Financial Times about the outlook for M&A deals in the pharma and biotech industries, particularly in light of Amgen’s recent agreement to buy Horizon Therapeutics for more than $28 billion, which is the largest pharma deal of the past two years.
“The most optimistic sign for me going into 2023 was the ease and rapidity with financing packages, even for some of the largest deals, were coming together in December,” said Frank.
Read “Pharma and biotech seek cure for industry deal slump.”
Subscribe to stay current on S&C Insights.
Sending an e-mail through this web site does not create an attorney-client relationship. You should not send us any information through this web site that you would want treated confidentially.